Highlights INmune Bio, Inc.

Equities

INMB

US45782T1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
10.11 ^USD	-0.10%		-9.49%	-10.21%

May. 09	Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000	MT
May. 09	Transcript : INmune Bio, Inc., Q1 2024 Earnings Call, May 09, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000	May. 09	MT
INmune Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial	Apr. 30	CI
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune?? Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 29	CI
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro? for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay	Apr. 23	CI
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024	Apr. 08	CI
INmune Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro	Mar. 05	CI
FDA Lifts Clinical Hold on INmune Bio Alzheimer's Program	Jan. 30	DJ
Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer?S Disease Program	Jan. 30	CI
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology	Jan. 16	CI
Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc..	Jan. 15	CI
INmune Bio, Inc. Announces First Patient Dosed in Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer	Jan. 02	CI
INmune Bio Alzheimer's Treatment Remains on Clinical Hold After FDA Requests Information; Shares Slump After Hours	Dec. 18	MT
INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA	Dec. 18	CI
Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium	Nov. 29	CI
INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease	Nov. 27	CI
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe	Nov. 15	CI
Earnings Flash (INMB) INMUNE BIO Reports Q3 Revenue $43,000	Nov. 01	MT
INmune Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights INmune Bio, Inc.

Equities

INMB

US45782T1051

Highlights

Filters